LXRX logo

LXRX
Lexicon Pharmaceuticals Inc

13,647
Mkt Cap
$529.14M
Volume
2.43M
52W High
$1.66
52W Low
$0.2836
PE Ratio
-7.65
LXRX Fundamentals
Price
$1.34
Prev Close
$1.45
Open
$1.49
50D MA
$1.38
Beta
1.66
Avg. Volume
2.42M
EPS (Annual)
-$0.6262
P/B
4.39
Rev/Employee
$301,757.28
Loading...
Loading...
News
all
press releases
Leerink Partnrs Has Pessimistic View of LXRX FY2028 Earnings
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2028 earnings per share estimates for shares of Lexicon Pharmaceuticals in a...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Wall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Hold
Wall Street Zen lowered shares of Lexicon Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·5d ago
News Placeholder
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 11.6% Higher - Should You Buy?
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 11.6% - Here's Why...
MarketBeat·9d ago
News Placeholder
What is HC Wainwright's Estimate for LXRX FY2025 Earnings?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Lexicon Pharmaceuticals in a note...
MarketBeat·11d ago
News Placeholder
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of +42.86% and +140.78%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -12.79% and -39.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of +112.50% and +344.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
Zacks·5mo ago

Latest LXRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.